For decades, women with BRCA1 and BRCA2 mutations have been told a frightening and often oversimplified message when entering menopause: hormone therapy is dangerous and should be avoided at all costs. As a physician working in menopause and genetics, and as a woman who deeply understands how disruptive menopause can be, I believe this narrative has done real harm.
New evidence is finally challenging that outdated thinking.
Recent data presented at the San Antonio Breast Cancer Symposium and summarized by FemTech World suggests that menopausal hormone therapy does not increase breast cancer risk in women with BRCA mutations who undergo menopause, including those who experience early surgical menopause after risk reducing ovary removal (American Association for Cancer Research, 2024; FemTech World, 2024).
In a prospective matched analysis of women with BRCA1 and BRCA2 mutations, researchers found no statistically significant increase in breast cancer risk among those who used menopausal hormone therapy compared with those who did not (Kotsopoulos et al., 2024). Even more compelling, estrogen only therapy was associated with a lower observed risk in this population (American Association for Cancer Research, 2024).
This matters deeply.
Women with BRCA mutations are often pushed into menopause years or even decades earlier than nature intended. The consequences are not trivial. Hot flashes, sleep disruption, mood changes, cognitive complaints, bone loss, cardiovascular risk, sexual dysfunction, and overall decline in quality of life are common and profound. Yet many of these women are told to simply endure their symptoms out of fear, often without being given updated evidence or individualized counseling.
As both a clinician and a woman in menopause myself, I find this unacceptable.
Much of the fear surrounding hormone therapy stems from older studies conducted in the general population, not in BRCA carriers. Those studies showed a modest increase in breast cancer risk primarily with long term combined estrogen and progestogen therapy, particularly when started later in life (Collaborative Group on Hormonal Factors in Breast Cancer, 2019). These findings were never meant to be applied universally, yet they were. Women with BRCA mutations were lumped into a category of automatic exclusion rather than thoughtful personalization.
What the newer data highlight is nuance.
In women with BRCA mutations, especially those who have undergone oophorectomy at a young age, hormone therapy may not only be safe but potentially protective depending on formulation, timing, and individual risk profile (Kotsopoulos et al., 2024). Certain combinations, including estrogen paired with selective estrogen receptor modulators, showed no breast cancer cases in small cohorts, suggesting promising alternatives that warrant further study (American Association for Cancer Research, 2024).
And yet, despite this growing body of evidence, many women remain misinformed, dismissed, or told that their suffering is the price they must pay for cancer prevention.
We can do better.
Menopause care must be evidence based, individualized, and rooted in respect for women’s lived experiences. BRCA status alone should not automatically disqualify someone from symptom relief, sleep restoration, bone protection, or cardiovascular support. Quality of life matters. Longevity matters. And informed choice matters.
This is not about pushing hormones on every woman. It is about giving women accurate information, modern data, and a seat at the decision making table. It is about acknowledging that fear based medicine has left too many women unnecessarily suffering.
Women deserve care that evolves with science.
Women deserve to be heard.
Women deserve better.
References
American Association for Cancer Research. (2024). Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations.
Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk. The Lancet, 394(10204), 1159 to 1168.
FemTech World. (2024). Menopausal hormone therapy may not increase breast cancer risk in women with BRCA mutations.
Kotsopoulos, J., Gronwald, J., Karlan, B. Y., et al. (2024). Hormone therapy use and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology.
Dr. Mia Chorney, DNP, FNPBC, MSCP
Co-Founder & Chief Medical Officer~The Pause Technologies Inc.
Scientific Advisory Board Member~Isagenix
Women’s Cardiovascular Health, Cardiovascular Genetics and Precision Medicine